Ombow, I'll have to check out MBRX. Looking through their recent press releases, I see in late March they announced plans for a $5.25 mil financing on the same day that they made a favorable clinical press release, and now they've done it again in April with a $15 mil financing following a favorable sounding press release.
So they sure don't waste time capitalizing on favorable news. It may look tacky to do that, but at least they 'got the money', which for a micro biotech is essential. They had the shelf registration in place and used it.
Annamycin sounds interesting, though I'll have to do some research. From my 'bio days' I remember that the anthracycline drugs had cardiac toxicity which limited their use, so if Annamycin is truly a safe anthracycline it could conceivably be a big breakthrough. I'll try to catch their webcast tomorrow.
>>> Our Next Generation Anthracycline, Annamycin, is unlike any currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients and is currently in two Phase I/II clinical trials. <<<
AI
